3 results
Approved WMOPending
Investigate the activity and safety of amrubicin alone versus amrubicin incombination with cisplatin versus standard treatment for extensive disease(ED) small-cell lung cancer in the first line setting.
Approved WMOCompleted
The primary objective is the Objective tumor response rate (RECIST). Secondary objectives are: duration of overall response, time to tumor progression (TTP), progression free survival (PFS), overall survival, toxicity profile, incidence of…
Approved WMOCompleted
The primary objective of this clinical study is to compare the incidence of post-repair wound related complications, including hernia occurence/reccurence between challenging abdominal wall defects repaired with Strattice Reconstructive Tissue…